Earnings Call Insights: Docusign (DOCU) Q1 fiscal 2027 Management View “We began fiscal 2027 with continued strong demand for DocuSign's AI-native Intelligent Agreement Management, or IAM platform,” said CEO Allan Thygesen, adding, “We have 40,000 companies invested in IAM and they generated 12.6% of total company ARR.” (President, CEO & Director Allan Thygesen) Thygesen highlighted product and pa...
Earnings Call Insights: Docusign (DOCU) Q1 fiscal 2027 Management View “We began fiscal 2027 with continued strong demand for DocuSign's AI-native Intelligent Agreement Management, or IAM platform,” said CEO Allan Thygesen, adding, “We have 40,000 companies invested in IAM and they generated 12.6% of total company ARR.” (President, CEO & Director Allan Thygesen) Thygesen highlighted product and partner expansion around IAM, including: “we made IAM more useful for in-house legal professionals by introducing a legal specific contract assistant and agents,” “we announced a deep Slack Integration,” and “Payments are also integrated into IAM through our partnership with Stripe.” (President, CEO & Director Thygesen) Management change was a notable update: “I also want to welcome our new Chief Product Officer, Graham Sheldon,” and “I also want to thank outgoing Chief Product Officer, Dmitri Krakovsky for his contribution to building IAM's foundation.” (President, CEO & Director Thygesen) CFO Blake Grayson tied Q1 execution to the transformation focus: “Our primary focus this year continues to be on transforming our business with IAM,” and “In Q1, we again increased our buyback activity, repurchasing $318 million in shares.” (Executive VP & CFO Blake Grayson) Outlook Grayson reiterated the company’s fiscal 2027 ARR growth view: “we continue to expect that our year-over-year growth rate range will be 8.25% to 8.75% or an 8.5% year-over-year increase to over $3.5 billion at the midpoint at the end of Q4 of fiscal 2027.” (Executive VP & CFO Grayson) On IAM mix goals, Grayson said, “We remain on track for IAM to represent approximately 18% of total ARR at fiscal year-end,” and “driving IAM to over $600 million in ARR by the end of this year.” (Executive VP & CFO Grayson) For revenue, Grayson guided: “we expect $865 million to $869 million in Q2,” and “$3.490 billion to $3.502 billion for fiscal 2027.” (Executive VP & CFO Grayson) Compared with last quarter’s framing, the compan...
Shares of cybersecurity platform provider CrowdStrike (NASDAQ:CRWD) fell 4.3% in the afternoon session after it reported Q1 FY2027 results that beat headline estimates on revenue, EPS, and net new ARR, however with the stock up 91% since its prior earnings release, the results did not scale to investor expectation.
Shares of cybersecurity platform provider CrowdStrike (NASDAQ:CRWD) fell 4.3% in the afternoon session after it reported Q1 FY2027 results that beat headline estimates on revenue, EPS, and net new ARR, however with the stock up 91% since its prior earnings release, the results did not scale to investor expectation.
herstockart/E+ via Getty Images The last time I spoke about Edgewise Therapeutics ( EWTX ) it was with a Seeking Alpha article entitled "Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst." With respect to this article, I mentioned that the company was in the process of developing its selective cardiac sarcomere modulator EDG-7500 for the treatment of patients with obstruc...
herstockart/E+ via Getty Images The last time I spoke about Edgewise Therapeutics ( EWTX ) it was with a Seeking Alpha article entitled "Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst." With respect to this article, I mentioned that the company was in the process of developing its selective cardiac sarcomere modulator EDG-7500 for the treatment of patients with obstructive hypertrophic cardiomyopathy [oHCM] and nonobstructive hypertrophic cardiomyopathy [nHCM] in the ongoing phase 2 CIRRUS-HCM study. I went over data the last time around showcasing that the drug did pretty well in terms of 4-week data from Part B and Part C of this trial, targeting patients with oHCM and nHCM, respectively. I also mentioned that the company was on track to release 12-week Part D data from this very same phase 2 study in Q2 of 2026. I had a "Buy" rating on this stock the last time around, and today I'm going to maintain this rating. The truth is that 12-week data from Part D of the phase 2 CIRRUS-HCM study is still expected in Q2 of 2026. Data from this is important to guide a phase 3 study for this program, which is expected to kick off in Q4 of 2026. In addition, the company is also making progress on initiating a phase 2 study using EDG-15400 to treat patients with heart failure with preserved ejection fraction [HFpEF] in 2026 as well. If everything is on track, then why do I believe that it is important to provide an update on this biotech at this time? The reason why is because there was a major shift in terms of its pipeline. It was able to sell off its muscular dystrophy program of sevasemten for the treatment of patients with Duchenne Muscular Dystrophy [DMD] and Becker Muscular Dystrophy [BMD] to Servier for an aggregate of $2.65 billion. What's the purpose of this? Well, the beauty is that the company is to use the cash to fully fund the entire EDG-7500 drug development program for the treatment of patients with oHCM/nHCM, potentially through po...